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ASSESSMENT OF LENGTH OF STAY FOR WOMEN WITH HIGH RISK 
COMORBIDITIES DURING LABOR AND DELIVERY
Patel AM, Syeda SS, Wu WK
St. John’s University, Queens, NY, USA
OBJECTIVES: Chronic co-morbid conditions during pregnancy have been associated
with poor maternal and infant health. Although studies have shown that women with 
anemia, diabetes or thyroid dysfunction during pregnancy are at high risk of complica-
tions in delivery, little is known about their impact on the length of hospitalization. 
The objective of this study was to identify the increased Length of Stay (LOS) of 
pregnant women with these high-risk comorbidities compared with other comorbidi-
ties, hospitalized for delivery and labor in the US. METHODS: The 2006 National
Hospital Discharge Survey (NHDS) was used as data source for the study. ICD-9-CM 
codes were reviewed to extract records of women with comorbid complications during 
labor and delivery (660.0–669.9) and to further identify women with high-risk comor-
bidity of anemia (648.0), diabetes (648.2) or thyroid dysfunction (648.1) complicating 
pregnancy, childbirth, and the puerperium. Survival analysis alongwith log rank test 
was used to evaluate the differences of LOS between patients with high risk comorbidi-
ties and low risk comorbidities. RESULTS: The 2006 NHDS recorded data for a total 
of 23,941 women with complications in delivery and labor. Among these, 2,490 
women had high risk comorbidities while 21,451 women had other comorbidities 
complicating their delivery and labor. The median LOS for women with high risk 
comorbidities (3 days) was 1 day higher compared to pregnant women with other 
co-morbidities (2 days; p  0.001). CONCLUSIONS: This study provides empirical
data on LOS for women with high risk comorbidities in the course of labor and
delivery. This result can be used as a basis by hospitals to assess their precautionary 
guidelines in pregnant women with high risk comorbidities to avoid additional LOS.
Further research can be performed to investigate the impact of demographic charac-
teristics and source of payment on the LOS of pregnant women with high risk 
comorbidities.
PIH2
CLINICAL AND COST OUTCOMES AMONG PATIENTS ON WARFARIN
WITH ELECTRONIC ALERTS TO REMIND PROVIDERS ABOUT HIGH
INTERNATIONAL NORMALIZED RATIO
Selvan MS, Peymann P, Flowers P, Murphy R, Shabot M
Memorial Hermann Healthcare System, Houston, TX, USA
OBJECTIVES: To understand beneﬁ ts and risks of backing out of an alert for warfarin 
administration when high International Normalized Ratio (INR). Adverse drug events
cause clinically signiﬁ cant adverse outcomes and complications 1–3. Analyses of a 
national surveillance study of showed that there were more than 175,000 visits for 
adverse drug events yearly, among them warfarin topped the list as the most commonly 
implicated medications. Such events are a huge economic burden to the nation impact-
ing patients in a myriad different ways. Therefore, it is widely thought that mitigating 
warfarin related complications could help decrease medical expenses. METHODS: We
developed an alert for our computerized pharmacy order system for all patients being
treated with warfarin. The system generated an alert during the ordering of warfarin
if the INR was q3.5. Upon encountering an alert providers had options such as back 
out from an order, or override, or override with some action. From June 1, 2007, to
November 30, 2008, our system had 12,041 inpatient encounters and received 21,234
orders for warfarin. We had 820 alerts for a total number of 635 encounters. The
mean warfarin dose was 4.76 mg. The mean INR for the 635 encounters with alert
was 4.24 with a standard deviation of 1.69. RESULTS: Average length of stay, average 
cost per case and complications were signiﬁ cantly lower among patients whose provid-
ers cancelled warfarin orders than patients who received by ignoring the alert. In
addition, providers who backed out from giving warfarin were more likely to prescribe
vitamin k which may have helped mitigate complications. There was no statistical 
signiﬁ cance in the hematoma related complications (1.7% versus 2.0%) between
backed out and overridden groups. CONCLUSIONS: Further investigation with addi-
tional factors is required before attributing the reduction in length of stay to backing
out of an alert.
PIH3
SYSTEMATIC LITERATURE REVIEW OF THE GYNECARE PROLIFT‚
PELVIC FLOOR REPAIR SYSTEM TREATMENT OUTCOMES
Sikirica V1, Robinson D1, Kirkemo A1, Hinoul P2, Meek J1, Jones SH1, Perkins HE1
1Ethicon, Inc a Johnson & Johnson Company, Somerville, NJ, USA, 2Ethicon, Inc a Johnson &
Johnson Company, CEDEX, France
OBJECTIVES: To summarize the efﬁ cacy/effectiveness, complications and patient
reported outcomes associated with the polypropylene mesh kit GYNECARE Prolift
Pelvic Floor Repair System. METHODS: A systematic literature review was conducted 
using MEDLINE, PUBMED and gynecologic conference abstracts from AUGS, IUGA
and SGS for primary research focusing on the use of GYNECARE Prolift from 
2005–2008. Included studies needed to report on outcomes after any GYNECARE 
Prolift regarding efﬁ cacy/effectiveness or safety of Anterior, Posterior or Total Repair. 
Single case studies, review articles, meta-analyses, non-English language studies and 
small case series (n  10) were excluded. Kin study results were included only from 
the primary article. Weighted averages and conﬁ dence intervals were calculated.
RESULTS: Among 33 independent studies included, mean (SD) follow-up time was
7.2 (4.6) months (95% CI: 7.0–7.4) among 24 studies reporting mean; and median 
follow-up reported was 7–19 months (data range: 2–30) for 9 studies. Objective ana-
tomic success rates were 89.5% (95% CI: 88.2–90.6; n  2614) for all GYNECARE 
Prolift, and 89.5% (86.5–92.0; n  532) for anterior, 92.0% (88.8–94.5; n  386) 
for posterior and 91.3% (87.6–94.2; n  311) for total repairs, respectively. Overall
recurrence rate (any compartment) was 9.3% (8.2–10.6; n  2217). Complication 
rates were: overall rate of any injury (Bladder, Bowel, Vaginal or Urethral) 1.7% 
(1.4–2.2; n  4,750) of which bladder injury/perforation was the highest relative to 
other rates: 2.3% (1.8–3.0; n  2486). Exposure rates were 6.9% (6.0–7.8; n  2985). 
Mesh excision/ resection was reported at 6.4% (5.1–8.1; n  1087). Dyspareunia 
rates were 6.7% (5.3–8.3; n  1092). Patient satisfaction was 82.3% (77.0–86.9; n 
244) and 87.5% reported they would “recommend to a friend” (81.0–92.4; n  144). 
CONCLUSIONS: The evidence for mesh-based repairs is growing. While more
randomized, and appropriately powered trials are needed to understand longer-
term outcomes, current peer-reviewed data shows that the GYNECARE Prolift kit 
is an effective pelvic ﬂ oor repair device with limited complications and high patient
satisfaction.
PIH4
PERSONALIZED MEDICINE: TRENDS IN CLINICAL STUDIES BASED ON 
NATIONAL REGISTRY DATA
Nellesen D, Person A, Yee K, Chawla A
Analysis Group, Inc., Menlo Park, CA, USA
OBJECTIVES: Targeted therapies using pharmacogenomic data promise to improve 
the safety, efﬁ cacy, and cost-effectiveness of drug treatment signiﬁ cantly. To assess 
research progress in targeting biopharmaceutical interventions to address unmet 
medical need, we investigated therapeutic, temporal, and economic trends in personal-
ized medicine using data from a national clinical trial registry. METHODS: Personal-
ized medicine (PM) is the use of a patient’s genotype or other molecular diagnostic 
(pharmacogenomic) data to guide a treatment decision. We queried ClinicalTrials.gov 
for studies using pharmacogenomic criteria for inclusion or exclusion, or for stratify-
ing outcomes, restricting our analysis to Phase III or IV studies initiated on or before 
January 7, 2009. We veriﬁ ed the sensitivity of our search strategy using a known set 
of studies for which PM-related trials have been conducted. RESULTS: As a result, 
1.7% (N  155) of registered Phase III/IV trials in the US (N  9,111) used pharma-
cogenomic data. Over time, the number of trials using pharmacogenomic data has 
increased greatly and, as expected, most PM trials (55%) were in the therapeutic areas 
of oncology and hematology. However, we observed a marked increase in the number 
of PM trials for drugs targeting disorders with highly variable treatment response,
such as neurology and mental health disorders including Alzheimer’s, depression, and
schizophrenia. In addition, we found that the source of funding for PM trials increas-
ingly comes from the pharmaceutical industry rather than from public sources. CON-
CLUSIONS: Targeting drugs to smaller subgroups is assumed to result in treating 
those patients most likely to respond and least likely to experience an adverse event. 
These data are consistent with the idea that these gains will be experienced broadly 
across therapeutic areas, however, the degree of impact will vary according to our
understanding of the molecular basis of disease, with associated implications for 
assessing relative clinical and cost effectiveness.
PIH5
AN ANALYSIS OF SELECT INJURY-INCREASING ANALGESIC 
MEDICATIONS IN MEDICARE DUAL ELIGIBLE ENROLLEES
Blackwell SA, Montgomery MA, Baugh DK, Ciborowski G, Levy JM
Centers for Medicare & Medicaid Services, Baltimore, MD, USA
OBJECTIVES: To assess the risk of injury associated with the use of select analgesics
in the elderly. METHODS: Logistic regression analysis performed to examine the risk 
of injury-related ER visits following the use of select analgesic medications. Demo-
graphic characteristics of CMS-HCC risk score, age, gender, and origin are reported 
as regressors. RESULTS: Separate analyses performed to assess the likelihood of an
injury-related emergency room visit when the reference group under study was mor-
phine, methadone, and propoxyphene recipients. For morphine, all medications ana-
lyzed were found to have a higher likelihood of an injury-related ER visit as compared
to morphine, except for fentanyl (p  0.05). Coding methadone as the reference group, 
only ketorolac, pentazocine and meperidine recipients had a higher likelihood of 
having an injury-related ER visit as compared to recipients of methadone (OR 1.411,
95% CI 1.301–1.530; OR 1.183, 95% CI 1.089–1.284; and OR1.181, 95% CI 
1.097–1.273, respectively). Designating propoxyphene as the reference group, only
ketorolac, pentazocine, meperidine, methadone, and hydrocodone recipients had a
higher likelihood (OR 1.470, 95% CI 1.367–1.581; OR 1.232, 95% CI 1.144–1.327; 
OR 1.231, 95% CI 1.153–1.314; OR 1.042, 95% CI 1.004–1.081; OR 1.047, 95% 
CI 1.038–1.057, respectively). Regarding demographics, Caucasian origin, male 
gender, middle-age elderly, and high CMS-HCC risk scores were found to be factors 
inﬂ uencing injury-related ER visits for elderly analgesic recipients. CONCLUSIONS:
Morphine is a very suitable opioid for use in the elderly. Methadone, a non-Beers
medication, is a problematic opioid needing further assessment by the clinical com-
munity for possible assignment to the Beers list. Propoxyphene, currently a low 
severity rated Beers medication, needs further assessment for possible reassignment to 
a high severity rating.
